Souhaitez-vous accéder aux communiqués récents ?

Press Release – No. 02 / 2020 Zealand Pharma hosts conference call on March 12 at 4 pm CET (10 am EST) to present full year results for 2019 Copenhagen, February 26, 2020 – Zealand Pharma A/S...

Press release – No. 01 / 2020 Zealand Pharma to attend 9th Annual SVB Leerink Global Healthcare Conference Copenhagen, February 20, 2020 – Chief Executive Officer Emmanuel Dulac and Chief...

Company announcement – No. 02 / 2020 Zealand Pharma major shareholder announcement: Wellington Management Group LLP Copenhagen, February 11, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL)...

Company announcement – No. 01 / 2020 Zealand Pharma announces bid to acquire Valeritas Zealand Pharma (NASDAQ: ZEAL) has submitted a bid to acquire substantially all assets of Valeritas Holdings,...

Company announcement – No. 49 / 2019 Total number of shares and voting rights in Zealand Pharma at December 31, 2019 Copenhagen, December 31, 2019 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL)...

Company announcement – No. 48 / 2019 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...

Company announcement – No. 47 / 2019 Zealand Pharma increases its share capital as a consequence of exercise of employee warrants Copenhagen, December 13, 2019 – Zealand Pharma A/S (“Zealand”)...

Company announcement – No. 46 / 2019 Zealand Pharma announces amendments to its Articles of Association following the granting of warrants Copenhagen, December 11, 2019 – Zealand Pharma...

Company announcement – No. 45 / 2019 Financial calendar for Zealand Pharma in 2020 Copenhagen, December 10, 2019 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR No. 20 04 50 78), a...

Company announcement – No. 44 / 2019 Zealand Pharma partner Beta Bionics receives FDA Breakthrough Device Designation for the iLet™ Bionic Pancreas System The iLet is a pocket-sized, wearable...